

**From:** Alexander Rogers <pharma@smiconferences.co.uk>  
**To:** Kester, Tonykester@aging.sc.gov  
**Date:** 1/16/2017 3:50:24 AM  
**Subject:** First Clinical Experience using mRNA Based Cancer Immunotherapy

---

## mRNA Cancer Vacs: Exclusive New Updates Unveiled by Scientific Pioneers at RNA Therapeutics 2017 [View details](#)

Dear Mr Tony Kester

According to a leading UK financial institute, **BioNTech RNA Pharmaceuticals**, one of Europe's largest private Biotechs, has been named as one of the **top 5 companies to watch** in 2017.

With hopes in being the first to develop and market the next generation disruptive immunotherapies, SMi Group will be welcoming their expertise at the 8th annual **RNA Therapeutics** conference when it returns to Central London next month.

**Day One** will feature a keynote from **BioNTech Vice President, RNA Biochemistry & Manufacturing, Andreas Kuhn**. The talk will offer exciting new developments into the first clinical experience using mRNA based cancer immunotherapy, as well as explore regulatory frameworks and GMP manufacturing.

In addition to chairing **Day Two** of the conference, **Henrich Haas, BioNTech's Vice President of RNA Formulation & Drug Delivery** will be providing case study insight into RNA-Lipoplexes in a presentation looking at intravenously injectable RNA Nanomedicines as Cancer Vaccines. With a progressive outlook into nucleic acid based nano-medicines, the talk will delve deeper into topics such as RNA delivery technologies, medical challenges, clinical testing and manufacturing.

Other notable speakers on the programme for RNA Therapeutics 2017 include:

- Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, **MiNA Therapeutics**
- Bo Rode Hansen, Global Head of RNA Therapeutics, **Roche**
- John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, **MHRA**
- Nicole Meisner-Kober, Senior Investigator, RNA Biology, **Novartis Institutes for Biomedical Research**
- Jeffrey Ulmer, Head of Pre-Clinical Research & Development, **GSK Vaccines USA**
- David Giljohann, CEO, **Excicure**
- Shai Erlich, Chief Medical Officer & President USA, **Quark Pharmaceuticals Inc**
- Amotz Shemi, CEO, **Silenseed**
- Sanyogitta Puri, Associate Principal Scientist, **AstraZeneca**

Download a brochure for further information at [www.therapeutics-rna.com](http://www.therapeutics-rna.com)

SMi Presents the  
8th Annual Show:

## **RNA** **Therapeutics 2017**

8th Annual Conference:  
22nd & 23rd February  
Workshops: 21st February

Copthorne Tara Hotel,  
London, UK

Proudly Sponsored by:  
Lipocalyx

---

Get Involved:

Register at [www.therapeutics-rna.com](http://www.therapeutics-rna.com)

For sponsorship enquiries  
contact Alia Malick on  
+44 (0)20 7827 6168  
or email [amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

For delegate enquiries  
contact Fateja Begum on  
+44 (0)20 7827 6184  
or email [fbegum@smi-online.co.uk](mailto:fbegum@smi-online.co.uk)

**REGISTER**

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565  
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>